Moderna’s RSV shot 83.7% effective, late-stage trial shows

By Paige Twentier for Becker’s Hospital Review on January 18, 2023

Moderna’s respiratory syncytial virus vaccine candidate for older adults is about 84 percent effective, its phase 3 study showed, and the company said it will seek approval this year.  Here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org